Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
MWN-AI** Summary
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company focused on innovative cancer immunotherapies, announced the upcoming presentation of data from its Phase 1 dose-escalation clinical study of BDC-3042 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, running from April 25-30, 2025. BDC-3042, a proprietary agonist antibody targeting dectin-2, aims to activate tumor-associated macrophages (TAMs) and is currently being evaluated in patients with advanced, metastatic solid tumors, including non-small cell lung cancer (NSCLC).
The study's findings will be presented by Dr. Ecaterina E. Dumbrava from The University of Texas MD Anderson Cancer Center during a poster session scheduled for April 29, 2025. Additionally, Bolt will showcase preclinical data from its Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs) targeting carcinoembryonic antigen (CEA) and PD-L1, reflecting the company's commitment to leveraging myeloid biology for enhanced cancer treatment.
The Boltbody ISAC platform represents a unique integration of targeting antibodies with immune stimulants, designed to initiate a robust immune response through myeloid cell recruitment and activation. This interconnected approach seeks to create a positive feedback loop that amplifies immune activity within the tumor microenvironment.
As part of its clinical pipeline, Bolt Biotherapeutics is also advancing BDC-4182, another ISAC candidate targeting claudin 18.2, and has plans to initiate clinical trials in the second quarter of 2025. The company continues to strengthen its portfolio through strategic collaborations with leading biopharmaceutical firms, aiming to enhance therapeutic options for cancer patients. For additional information on their upcoming presentations, the details can be accessed on the AACR website and the Bolt Biotherapeutics website.
MWN-AI** Analysis
As Bolt Biotherapeutics (NASDAQ: BOLT) prepares to present critical Phase 1 clinical trial data for its investigational therapy, BDC-3042, at the AACR Annual Meeting 2025, investors should take note of several key factors that could impact the company's market performance in the coming months.
BDC-3042, a first-in-class agonist targeting dectin-2 expressed on tumor-associated macrophages, has the potential to significantly advance the immunotherapy landscape, especially for patients with advanced solid tumors such as non-small cell lung cancer. The results presented during the conference could be pivotal, both in validating the efficacy of BDC-3042 and in influencing investor sentiment. Positive data will likely draw interest from institutional investors and catalyze increased trading volumes, potentially lifting share prices. Conversely, any disappointing results may prompt volatility and a reevaluation of market positioning.
Additionally, Bolt’s broader pipeline, which includes the Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs), presents another source of growth. The focus on innovative strategies, targeting CEA and PD-L1 in conjunction with BDC-3042, highlights Bolt’s commitment to addressing critical unmet needs in oncology, appealing to long-term investors.
Investors should also consider the systemic market sentiment towards biopharmaceuticals and immunotherapies, as they can create substantial headwinds or tailwinds. Given recent advancements in targeted treatments and heightened competition, staying abreast of industry trends is essential.
In conclusion, while the upcoming data presentation at AACR is a significant near-term catalyst for Bolt Biotherapeutics, potential investors should weigh this against broader industry factors and company fundamentals. Monitoring the reception of the data and comments from analysts post-presentation will provide insights into the stock’s direction and longer-term growth prospects.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with metastatic or unresectable solid tumors including non-small cell lung cancer (NSCLC).
Bolt will also be presenting preclinical data from two of its pipeline programs, Boltbody™ ISACs targeting CEA and PD-L1.
Details about the poster presentations can be found below and on the AACR website. Additionally, a copy of each poster will be available on the Publications page of the Bolt Biotherapeutics website at the start of each poster session.
Title: BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study
Presenter: Ecaterina E. Dumbrava, M.D., The University of Texas MD Anderson Cancer Center
Poster Session: First-in-Human Phase I Clinical Trials 2
Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Location: Poster Section 48
Poster Number: 20
Abstract Number: CT154
Title: A highly efficacious next-generation CEACAM5 (CEA)-targeted Boltbody™ ISAC for the treatment of colorectal, pancreatic and lung tumors
Presenter: Paul D. Ponath, Ph.D., Bolt Biotherapeutics
Poster Session: T Cell Engagers and Novel Antibody-Based Therapies
Session Date and Time: Wednesday, April 30, 2025, 9:00 a.m. – 12:00 p.m. CDT
Location: Poster Section 40
Poster Number: 25
Abstract Number: 7399
Title: PD-L1-directed ISACs target host immune cells to drive powerful antitumor immune responses in a manner distinct from conventional PD-1/PD-L1 blockade
Presenter: Justin A. Kenkel, Ph.D., Bolt Biotherapeutics
Poster Session: T Cell Engagers and Novel Antibody-Based Therapies
Session Date and Time: Wednesday, April 30, 2025, 9:00 a.m. – 12:00 p.m. CDT
Location: Poster Section 40
Poster Number: 19
Abstract Number: 7333
About the Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Platform
Bolt Biotherapeutics’ Boltbody ISAC platform harnesses the precision of antibodies with the power of the innate and adaptive immune system to generate a productive anti-cancer response. Each Boltbody ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant. The antibody is designed to target one or more markers on the surface of a tumor cell and the immune stimulant is designed to recruit and activate myeloid cells. Activated myeloid cells initiate a positive feedback loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This increases the population of activated immune system cells in the tumor microenvironment and promotes a robust immune response with the goal of generating durable therapeutic responses for patients with cancer.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in second quarter 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com
FAQ**
How does Bolt Biotherapeutics Inc. BOLT plan to leverage the data from the Phase 1 study of BDC-3042 presented at the AACR Annual Meeting to enhance its clinical development strategy and investor confidence?
What are the anticipated milestones for Bolt Biotherapeutics Inc. BOLT following the results of the BDC-3042 Phase 1 trial, particularly regarding its next-generation Boltbody ISAC programs?
Can Bolt Biotherapeutics Inc. BOLT provide insights on the potential competitive advantages of its proprietary Boltbody ISAC platform compared to conventional cancer therapies?
What collaborations or partnerships is Bolt Biotherapeutics Inc. BOLT exploring to support the development and commercialization of its innovative cancer therapies in the near future?
**MWN-AI FAQ is based on asking OpenAI questions about Bolt Biotherapeutics Inc. (NASDAQ: BOLT).
NASDAQ: BOLT
BOLT Trading
-1.18% G/L:
$4.18 Last:
7,682 Volume:
$4.26 Open:
